Concepts for the treatment of Alzheimer's disease: Molecular mechanisms and clinical application

International Journal of Experimental Pathology

Volumn 86, Issue 3, 2005, Pages 173-185

  Pietrzik, Claus ^a   Behl, Christian ^b,c  

^a Department of Molecular Neurodegeneration ^*  (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Alzheimer's disease; APP; Experimental concepts; Prevention; Tau protein; Therapy

Indexed keywords

ACETYLCHOLINE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHELATING AGENT; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HORMONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL RESEARCH; DEGENERATIVE DISEASE; DRUG RESEARCH; EXPERIMENTAL THERAPY; HUMAN; NEUROCHEMISTRY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SYMPTOM; TREATMENT PLANNING;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; CELL DEATH; ENDOPEPTIDASES; GLUTAMATES; HOMEOSTASIS; HORMONES; HUMANS; OXIDATIVE STRESS; PROTEASE INHIBITORS; TAU PROTEINS;

EID: 20444475400     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0959-9673.2005.00435.x     Document Type: Review

References (74)

1. Akiyama H., Barger S., Barnum S. et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
2. Albers D.S. & Beal M.F. (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm. Suppl. 59, 133-154.
3. Anderson G.L., Limacher M., Assaf A.R. et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health Initiative randomized controlled trial. JAMA 291, 1701-1712.
4. Annaert W., De Strooper B. (1999) Presenilins: molecular switches between proteolysis and signal transduction. Trends Neurosci. 22, 439-443.
5. Atwood C.S., Moir R.D., Huang X. et al. (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273, 12817-12826.
6. Atwood C.S., Scarpa R.C., Huang X. et al. (2000) Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid betal-42. J. Neurochem. 75, 1219-1233.
7. Behl C. (2002) Oestrogen as a neuroprotective hormone. Nat Rev. Neurosci. 3, 433-442.
8. Blacker D. & Tanzi R.E. (1998) The genetics of Alzheimer disease: current status and future prospects. Arch. Neurol. 55, 294-296.
9. Bliss T.V. & Collingridge G.L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31-39.
10. Cao X. & Sudhof T.C. (2001) A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115-120.
11. Cao X. & Sudhof T.C. (2004) Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J. Biol. Chem. 279, 24601-24611.
12. Cherny R.A., Atwood C.S., Xilinas M.E. et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676.
13. Cherny R.A., Legg J.T., McLean C.A. et al. (1999) Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J. Biol. Chem. 274, 23223-23228.
14. Christen Y. (2000) Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71, 621S-629S.
15. Citron M. (2004a) Beta-secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol. Sci. 25, 92-97.
16. Citron M. (2004b) Strategies for disease modification in Alzheimer's disease. Nat Rev. Neurosci. 5, 677-685.
17. Cummings J.L. (2004) Alzheimer's disease. N. Engl. J. Med. 351, 56-67.
18. Dartigues J.F. & Letenneur L. (2000) Genetic epidemiology of Alzheimer's disease. Curr. Opin. Neurol. 13, 385-389.
19. Davis K.L., Mohs R.C., Marin D. et al. (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281, 1401-1406.
20. De Strooper B., Saftig P., Craessaerts K. et al. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390.
21. DeKosky S.T., Ikonomovic M.D., Styren S.D. et al. (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 51, 145-155.
22. Edbauer D., Winkler E., Regula J.T., Pesold B., Steiner H., Haass C. (2003) Reconstitution of gamma-secretase activity. Nat Cell Biol. 5, 486-488.
23. Fassbender K., Simons M., Bergmann C. et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 5856-5861.
24. Greenamyre J.T. & Porter R.H. (1994) Anatomy and physiology of glutamate in the CNS. Neurology 44, S7-S13.
25. Haass C. (2004) Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 23, 483-488.
26. Hebert L.E., Scherr P.A., Beckett L.A. et al. (1995) Age-specific incidence of Alzheimer's disease in a community population. JAMA 273, 1354-1359.
27. Hock C., Konietzko U., Streffer J.R. et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
28. Holsinger R.M., McLean C.A., Beyreuther K., Masters C.L., Evin G. (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann. Neurol. 51, 783-786.
29. Hooper N.M., Trew A.J., Parkin E.T., Turner A.J. (2000) The role of proteolysis in Alzheimer's disease. Adv. Exp. Med. Biol. 477, 379-390.
30. Hoyer S, & Riederer P. (2003) Pathomechanisms and hypothesis-guided therapeutic strategies for late-onset Alzheimer's disease. Fortschr. Neurol. Psychiatr. 71 (Suppl. 1), S16-S26.
31. Hutton M., Lendon C.L., Rizzu P. et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
32. Kitazume S., Tachida Y., Oka R., Shirotani K., Saido T.C., Hashimoto Y. (2001) Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl. Acad. Sci. USA 98, 13554-13559.
33. Koo E.H. & Squazzo S.L. (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386-17389.
34. Kopan R. & Ilagan M.X. (2004) Gamma-secretase: proteasome of the membrane? Nat Rev. Mol Cell Biol. 5, 499-504.
35. Lanctot K.L., Herrmann N., Yau K.K. et al. (2003) Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 169, 557-564.
36. Lane R.M., Kivipelto M., Greig N.H. (2004) Acetylcholinesterase and its inhibition in Alzheimer disease. Clin. Neuropharmacol. 27, 141-149.
37. Lichtenthaler S.F., DomingueZ D.I., Westmeyer G.G. et al. (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278, 48713-48719.
38. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52.
39. McEwen B.S. (2001) Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J. Appl. Physiol. 91, 2785-2801.
40. Molinuevo J.L., Garcia-Gil V., Villar A. (2004) Memantine: an antiglutamatergic option for dementia. Am. J. Alzheimers Dis. Other Demen. 19, 10-18.
41. Monsonego A. & Weiner H.L. (2003) Immunotherapeutic approaches to Alzheimer's disease. Science 302, 834-838.
42. Moosmann B. & Behl C. (2002) Antioxidants as treatment for neurodegenerative disorders. Expert Opin. Investig. Drugs 11, 1407-1435.
43. Moosmann B. & Behl C. (2004) Selenoprotein synthesis and side-effects of statins. Lancet 363, 892-894.
44. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448-452.
45. Nunomura A., Perry G., Aliev G. et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767.
46. Pietrzik C.U., Busse T., Merriam D.E., Weggen S., Koo E.H. (2002) The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 21, 5691-5700.
47. Pietrzik C.U., Yoon I.S., Jaeger S., Busse T., Weggen S., Koo E.H. (2004) FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J. Neurosci. 24, 4259-4265.
48. Postina R., Schroeder A., Dewachter I. et al. (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113, 1456-1464.
49. Pratico D. & Delanty N. (2000) Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 109, 577-585.
50. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. (2003) Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333-1341.
51. Ritchie C.W., Bush A.I., Mackinnon A. et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685-1691.
52. Robinson S.R. & Bishop G.M. (2002) Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol. Aging 23, 1051-1072.
53. Rogers J., Cooper N.R., Webster S. et al. (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 89, 10016-10020.
54. Saura C.A., Choi S.Y., Beglopoulos V. et al. (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42, 23-36.
55. Scarpini E., Scheltens P., Feldman H. (2003) Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2, 539-547.
56. Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
57. Scott L.J. & Goa K.L. (2000) Galantamine: a review of its use in Alzheimer's disease. Drugs 60, 1095-1122.
58. Selkoe D.J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
59. Selkoe D. & Kopan R. (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26, 565-597.
60. Sies H. (1986) Biochemistry of oxidative stress. Angew. Chem. Int. Ed. Engl. 25, 1058-1071.
61. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti G.G., Simons K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95, 6460-6464.
62. Simons M., Schwarzler F., Lutjohann D. et al. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346-350.
63. Stewart W.F., Kawas C., Corrada M., Metter E.J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
64. Sucher N.J., Awobuluyi M., Choi Y.B., Lipton S.A. (1996) NMDA receptors: from genes to channels. Trends Pharmacol. Sci. 17, 348-355.
65. Szekely C.A., Thorne J.E., Zandi P.P. et al. (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23, 159-169.
66. Teller J.K., Russo C., DeBusk L.M. et al. (1996) Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2, 93-95.
67. Terry R.D. (1996) The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 55, 1023-1025.
68. United Nations, Department of Economic and Social Affairs, Population Division (2002) World Population Ageing: 1950-2050. Report as a contribution to the 2002 World Assembly on Ageing.
69. Weggen S., Eriksen J.L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.
70. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. (1981) Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10, 122-126.
71. Winkler J., Thal L.J., Gage F.H., Fisher L.J. (1998) Cholinergic strategies for Alzheimer's disease. J. Mol. Med. 76, 555-567.
72. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398, 513-517.
73. Wolozin B. (2002) Cholesterol and Alzheimer's disease. Biochem. Soc. Trans. 30, 525-529.
74. Zandi P.P., Anthony J.C., Khachaturian A.S. et al. (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 61, 82-88.